Reducing the global burden of HTLV-1 infection: An agenda for research and action

Archive ouverte

Willems, Luc | Hasegawa, Hideki | Accolla, Roberto | Bangham, Charles | Bazarbachi, Ali | Bertazzoni, Umberto | Carneiro-Proietti, Anna Barbara de Freitas | Cheng, Hua | Chieco-Bianchi, Luigi | Ciminale, Vincenzo | Coelho-Dos-Reis, Jordana | Esparza, José | Gallo, Robert | Gessain, Antoine | Gotuzzo, Eduardo | Hall, William | Harford, Joseph | Hermine, Olivier | Jacobson, Steven | Macchi, Beatrice | Macpherson, Calum | Mahieux, Renaud | Matsuoka, Masao | Murphy, Edward | Peloponese, Jean-Marie | Simon, Viviana | Tagaya, Yutaka | Taylor, Graham | Watanabe, Toshiki | Yamano, Yoshihisa

Edité par CCSD ; Elsevier Masson -

International audience. Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion